SCYNEXIS Inc SCYX

Healthcare

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

NDAQ:SCYX - Post by User

SCYNEXIS Inc > scyx needs to find financial backing

<< Previous

Bullboard Posts

Next >>

Comment by JonathanJSmithon Apr 27, 2021 10:26am

77 Views

Post# 33073808

RE:RE:RE:scyx needs to find financial backing

Dude,

They have enough money to last until 2023 ($93MM) according to recent filings. Currently, they have ~20MM shares outstanding; fully diluted, this number is ~40MM however, that includes another $105MM in cash for those 20MM shares (which they've yet to receive). Effectively, they have access to over $200MM. Furthermore, with their drug about to be approved (fingers crossed as I am long), that money should extend their runway considerably.

I don't anticipate further dilution any time in the foreseeable future.

Cheers,

JJ

<< Previous

Bullboard Posts

Next >>

Junior helium stock to benefit from new legislation in U.S.